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Nucleoside reverse-transcriptase inhibitor cross-resistance 
and outcomes from second-line antiretroviral therapy in the 
public health approach: an observational analysis within the 
randomised, open-label, EARNEST trial
Nicholas I Paton, Cissy Kityo, Jennifer Thompson, Immaculate Nankya, Leonard Bagenda, Anne Hoppe, James Hakim, Andrew Kambugu, 
Joep J van Oosterhout, Mary Kiconco, Silvia Bertagnolio, Philippa J Easterbrook, Peter Mugyenyi, A Sarah Walker, for the Europe Africa Research 
Network for Evaluation of Second-line Therapy (EARNEST) Trial Team*
Summary
Background Cross-resistance after first-line antiretroviral therapy (ART) failure is expected to impair activity of 
nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence for the 
effect of cross-resistance on virological outcomes is limited. We aimed to assess the association between the activity, 
predicted by resistance testing, of the NRTIs used in second-line therapy and treatment outcomes for patients infected 
with HIV.
Methods We did an observational analysis of additional data from a published open-label, randomised trial of second-
line ART (EARNEST) in sub-Saharan Africa. 1277 adults or adolescents infected with HIV in whom first-line ART 
had failed (assessed by WHO criteria with virological confirmation) were randomly assigned to a boosted protease 
inhibitor (standardised to ritonavir-boosted lopinavir) with two to three NRTIs (clinician-selected, without resistance 
testing); or with raltegravir; or alone as protease inhibitor monotherapy (discontinued after week 96). We tested 
genotypic resistance on stored baseline samples in patients in the protease inhibitor and NRTI group and calculated 
the predicted activity of prescribed second-line NRTIs. We measured viral load in stored samples for all patients 
obtained every 12–16 weeks. This trial is registered with Controlled-Trials.com (number ISRCTN 37737787) and 
ClinicalTrials.gov (number NCT00988039).
Findings Baseline genotypes were available in 391 (92%) of 426 patients in the protease inhibitor and NRTI group. 
176 (89%) of 198 patients prescribed a protease inhibitor with no predicted-active NRTIs had viral suppression (viral 
load <400 copies per mL) at week 144, compared with 312 (81%) of 383 patients in the protease inhibitor and raltegravir 
group at week 144 (p=0·02) and 233 (61%) of 280 patients in the protease inhibitor monotherapy group at week 96 
(p<0·0001). Compared with results with no active NRTIs, 95 (85%) of 112 patients with one predicted-active NRTI had 
viral suppression (p=0·3) and 20 (77%) of 26 patients with two or three active NRTIs had viral suppression (p=0·08). 
Over all follow-up, greater predicted NRTI activity was associated with worse viral load suppression (global p=0·0004).
Interpretation Genotypic resistance testing might not accurately predict NRTI activity in protease inhibitor-based 
second-line ART. Our results do not support the introduction of routine resistance testing in ART programmes in 
low-income settings for the purpose of selecting second-line NRTIs.
Funding European and Developing Countries Clinical Trials Partnership, UK Medical Research Council, Institito de 
Salud Carlos III, Irish Aid, Swedish International Development Cooperation Agency, Instituto Superiore di Sanita, 
WHO, Merck. 
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
More than 17 million people receive antiretroviral therapy 
(ART) for HIV infection, mainly delivered with the WHO-
recommended public health approach, characterised by 
use of standardised sequential regimens.1,2 Standardised 
first-line and second-line regimens both include 
nucleoside reverse-transcriptase inhibitors (NRTIs), 
combined with a non-NRTI (NNRTI) in first-line and a 
boosted protease inhibitor in second-line therapy.3 
Treatment guidelines for individualised therapy in high-
income settings generally recommend that resistance 
testing be done at the time of first-line failure, because of 
the assumption that choosing more active NRTI drugs 
(those with less predicted cross-resistance) will probably 
optimise outcomes.4–6 However, in programmes that have 
adopted the public health approach, in which patients 
often have prolonged exposure to a failing first-line 
regimen (because diagnosis of failure is delayed by 
limited access to viral load monitoring) with extensive 
cross-resistance to second-line NRTIs (which is usually 
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undetected, because resistance testing is not done 
routinely), treatment outcomes seem excellent.7,8 This 
suggests that, in the setting of protease inhibitor-based 
second-line therapy, greater cross-resistance and lower 
predicted activity of NRTIs do not greatly affect outcomes. 
Such a scenario might reduce the potential benefit that 
could be gained from the introduction of resistance 
testing into the public health approach for second-line 
NRTI drug selection. We aimed to assess the association 
between the activity, predicted by resistance testing, of the 
NRTIs used in second-line therapy and treatment 
outcomes for patients with HIV.
Methods
Study design and patients
We did an observational analysis within an open-label, 
randomised trial of second-line ART (EARNEST) in 
sub-Saharan Africa. The EARNEST trial,7 done from 
2010–14 in 14 clinical sites in Uganda, Zimbabwe, Malawi, 
Kenya, and Zambia, enrolled adults and adolescents older 
than 12 years infected with HIV in whom first-line 
NNRTI-based regimens had failed (by WHO clinical, 
immunological, or virological criteria, all confirmed by 
viral load >400 copies per mL; and with no more than 
three missed ART doses reported in the previous 
1 month). The EARNEST trial protocol (including viral 
load and genotyping sub-studies described here) was 
approved by ethics committees in participating countries 
and the UK. All patients or caregivers provided written 
informed consent.
Eligible patients were randomly assigned using 
computer-generated randomisation list with variable 
block size to receive a protease inhibitor (standardised 
to ritonavir-boosted lopinavir) together with two or 
Research in context
Evidence before this study
We searched PubMed with no start date or language restrictions 
for articles published until Aug 1, 2016, with the terms 
“second-line therapy”, “protease inhibitors”, “resistance testing”, 
and the individual drug names, and we also reviewed relevant 
HIV conference abstracts. This search identified studies that 
examined the association between nucleoside 
reverse-transcriptase inhibitor (NRTI) resistance and virological 
outcomes for NRTI plus protease inhibitor second-line therapy 
after failure on a first-line non-NRTI (NNRTI)-containing 
regimen. We found two cohort studies done in sub-Saharan Africa 
(243 and 101 participants, follow-up 12 months) and one in Asia 
(105 participants, follow-up 12 months) and analyses of the NRTI 
plus protease inhibitor arm in two randomised controlled trials 
(254 participants, follow-up 48 weeks; 270 participants, 
follow-up 96 weeks). These studies either reported no association 
or an inverse association between predicted activity of prescribed 
NRTIs and viral load suppression.
Added value of this study
In the EARNEST trial, we prospectively followed up a large group 
of HIV-infected patients taking a protease inhibitor and NRTI 
second-line regimen and collected adherence data and relevant 
outcome data, including viral load, with greater frequency and 
with lower incidence of loss-to-follow-up than in preceding 
cohort studies. This trial was also larger (426 patients on 
protease inhibitor and NRTI) than the other two randomised 
controlled trials of second-line therapy and had longer follow-up 
(144 weeks). Our analysis shows that a regimen containing 
NRTIs with no or limited predicted activity achieved viral load 
suppression in a high proportion of patients, which was 
sustained throughout longer-term follow-up. The size and 
duration of our study also allows for a more robust model for 
analysing predictors of outcome than previous studies: we found 
a paradoxical inverse association between extent of baseline 
resistance and viral suppression (noted in several, but not all, 
previous analyses) but were also able to show more clearly that 
this inverse association persisted after adjustment for other 
relevant factors including baseline viral load and CD4 cell count 
and adherence during follow-up (adherence was proposed as the 
probable explanation for the inverse association by several 
previous studies). The main added value of this analysis is the 
availability of two comparison groups within the same trial, 
allowing us to show the contribution of the NRTIs to regimen 
activity. In the group with no predicted active NRTIs in the 
prescribed regimen, viral load suppression was at least as good as 
that of a regimen containing a predicted fully active drug from a 
new drug class (raltegravir) and clearly superior to that obtained 
with the protease inhibitor used alone. Thus the good outcomes 
obtained with a protease inhibitor and NRTI second-line regimen 
in programme settings are not solely attributable to the high 
potency of protease inhibitors (proposed as the explanation in 
some earlier studies) but also reflect a substantial additional 
contribution from NRTIs predicted to have limited or no activity 
as a result of cross-resistance.
Implications of all the available evidence
Despite extensive cross-resistance, NRTIs make a major 
contribution to viral load suppression in second-line therapy 
when combined with a protease inhibitor. Predictions based on 
genotypic resistance testing appear to overestimate the 
detrimental effect of resistance mutations on the activity of 
NRTIs and should be re-examined for use in the context of 
second-line switch to a protease inhibitor-based regimen and 
possibly for other specific regimen changes. Taken together, the 
data support WHO treatment guidelines that do not 
recommend resistance testing at switch to second-line therapy. 
Adherence seems to be an important determinant of outcomes 
in second-line therapy and NRTI selection might best be based 
on minimising toxicity and maximising tolerability, in view of 
the effect that these might have on adherence.
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three NRTIs (protease inhibitor and NRTI group), or 
with raltegravir (protease inhibitor and raltegravir group), 
or alone as monotherapy (following an initial induction 
with 12 weeks’ raltegravir; protease inhibitor monotherapy 
group). In the protease inhibitor and NRTI group, NRTIs 
were selected by clinicians (without resistance testing) 
on the basis of NRTIs used first-line, side-effects, local 
standard-of-care, drug availability, and WHO guidelines 
(tenofovir and lamivudine or emtricitabine used if 
zidovudine or stavudine was used in first-line; zidovudine 
and lamivudine used if tenofovir was used in first-line).
Procedures
Patients were followed for 144 weeks with clinic visits 
every 1–2 months. Adherence was assessed by structured 
questions and intensive adherence counselling was given 
when lapses were identified. Treatment was monitored 
clinically and with CD4 cell counts every 12–16 weeks.
We measured viral load on stored samples in a central 
laboratory (JCRC, Kampala, Uganda) with the Abbott 
RealTime HIV-1 assay (Abbott Laboratories, Chicago, IL, 
USA) at weeks 4, 12, 24, 36, 48, 60, 80, 96, 110, 126 and 144. 
In the protease inhibitor monotherapy group, viral load 
was tested at all timepoints to week 48, and at week 96, 
after which the group was discontinued. Viral load results 
were reviewed by a data monitoring committee, but not 
returned to managing physicians.7
We genotyped reverse transcriptase on all available 
baseline samples in the protease inhibitor and NRTI 
group using a WHO-accredited in-house assay9 at JCRC. 
We used the Stanford algorithm (version 7) to predict 
drug susceptibility.
We calculated the number of predicted-active NRTIs in 
the prescribed second-line regimen by counting the 
NRTI drugs initially prescribed that had no more than 
low-level resistance (ie, not intermediate or high level 
resistance) predicted from baseline genotyping. We also 
calculated the genotypic susceptibility score10 for the 
prescribed second-line NRTIs by assigning a score of 0 
(high-level resistance), 0·25 (intermediate resistance), 
0·50 (low-level resistance), 0·75 (potential low-level 
resistance), and 1 (susceptible) to each prescribed NRTI.
Statistical analysis
Analyses were by intention-to-treat (ie, including patients 
regardless of subsequent treatment changes) and based 
on observed viral loads (ie, not imputing missing viral 
load data). We used generalised estimating equations 
(independent working correlation structure, binomial 
distribution, and robust variance) to test differences 
between treatment groups in the proportion of patients 
with virological suppression across the whole follow-up 
period. Risk differences were used to compare groups 
at the latest timepoint in the study (week 144; or week 96 
for the protease inhibitor monotherapy group because 
this group was discontinued early). We used logistic 
multivariable regression with fractional polynomials and 
backwards elimination (exit p>0·05, stata command 
mfp) to identify independent predictors of a viral load of 
less than 400 copies per mL at week 144 in complete cases 
in the protease inhibitor and NRTI group. Variables 
included in the analysis were age (continuous), sex, 
viral subtype, proportion of visits missed or when 
non-adherence was self-reported (continuous), years on 
first-line ART (continuous), history of ever smoking, 
ever drinking alcohol, years of education, job status 
(employed, student, or unemployed), hours worked 
if employed (continuous), household income (<US$50, 
$50–200, or >$200 per month), availability of food for 
regular meals, clinical history (diabetes, tuberculosis, 
CNS disease, cardiovascular disease), and, at switch to 
second-line, viral load, CD4 cell count, haemoglobin, 
blood glucose, and estimated glomerular filtration rate 
(eGFR; all continuous). We tested the additional effect of 
individual mutations, pairs of mutations with more than 
10% prevalence, and the presence of mutations in the 
well recognised thymidine analogue mutations type 1 
(TAM1; ie, 41Leu, 210Trp, or 215Tyr) and type 2 (TAM2; 
ie, 67Asn, 70Arg, 215Phe, or 219Gln) pathways one at a 
time in the selected model. We also did two sensitivity 
analyses, first without backwards elimination including 
all factors with p<0·2 on univariable analysis (appendix 
p 6–7), and second with backwards elimination with 
exit p>0·2. We used Stata (version 13.1) for all analyses.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Between April 12, 2010, and April 29, 2011, 1277 patients 
were randomly assigned (426 to protease inhibitor and 
NRTI, 433 to protease inhibitor and raltegravir, 418 to 
protease inhibitor monotherapy). Baseline characteristics 
were similar between the groups (42% had viral 
load >100 000 copies per mL, 62% had CD4 cell count 
<100 cells per mL).7 At 144 weeks, 106 (8%) had died 
and 30 (2%) had withdrawn or were lost to follow-up. 
The protease inhibitor monotherapy group changed to 
combination therapy (mostly adding NRTIs) following 
review of the week 96 results by the data monitoring 
committee; two participants in the protease inhibitor and 
NRTI group switched for failure by week 144; no patients 
in the protease inhibitor and raltegravir group switched 
for failure. Viral load results were available from 
12 327 (91%) of 13 481 scheduled follow-up timepoints 
until death, last follow-up, or lost to follow-up.
Baseline genotypes were available for 391 (92%) of 
426 participants in the protease inhibitor and NRTI 
group. 95% had at least one NRTI mutation (table 1). 
230 patients (59%) had no predicted-active NRTIs in 
For the Stanford University HIV 
Drug Resistance Database see 
http://hivdb.stanford.edu
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Total Number of predicted-active NRTIs in second-line regimen
0 1 ≥2
Baseline genotype results available 391 230 128 33
GSS of prescribed NRTIs 0·25 (0–1; 0–3) 0 (0–0·25; 0–0·5) 1 (0·5–1; 0·5–1·25) 2 (2–2; 1–3)
Country
Malawi* 37 (9%) 17 (7%) 8 (6%) 12 (36%)
Uganda 253 (65%) 154 (67%) 87 (68%) 12 (36%)
Zimbabwe 84 (21%) 56 (24%) 21 (16%) 7 (21%)
Kenya 17 (4%) 3 (1%) 12 (9%) 2 (6%)
Age (years) 37 (31–43) 37 (31–43) 37 (31–45) 36 (24–41)
Years on first line ART 4·0 (2·8–5·4) 4·1 (2·9–5·5) 4·2 (2·7–5·3) 2·8 (2·3–5·0)
Viral load (copies per mL) 68 359 (23 200–181 887) 83 634 (34 800–222 514) 47 733 (13 683–94 293) 113 982 (10 683–325 122)
>100 000 158 (40%) 110 (48%) 29 (23%) 19 (58%)
CD4 (cells per µL) 69 (28–136) 47 (21–98) 116 (64–183) 91 (50–177)
≤100 247 (63%) 174 (76%) 54 (42%) 19 (58%)
Number of NRTI mutations 4 (2–5) 5 (4–5) 2 (2–3) 0 (0–1)
Any NRTI mutation 370 (95%) 230 (100%) 128 (100%) 12 (36%)
Any TAM1 mutations 211 (54%) 173 (75%) 38 (30%) 0
Any TAM2 mutations 220 (56%) 159 (69%) 60 (47%) 1 (3%)
Most common NRTI mutations
Met184Val 355 (91%) 217 (94%) 126 (98%) 12 (36%)
Met41Leu 170 (43%) 158 (69%) 12 (9%) 0
Thr215Tyr 167 (43%) 137 (60%) 30 (23%) 0
Asp67Asn 150 (38%) 126 (55%) 24 (19%) 0
Lys70Arg 125 (32%) 81 (35%) 43 (34%) 1 (3%)
Leu210Trp 118 (30%) 110 (48%) 8 (6%) 0
Thr215Phe 97 (25%) 75 (33%) 22 (17%) 0
Lys219Gln 66 (17%) 42 (18%) 24 (19%) 0
Lys219Glu 44 (11%) 40 (17%) 4 (2%) 0
Lys65Arg 29 (7%) 25 (11%) 4 (2%) 0
Most common NRTI mutation pattern
41Leu, 184Val, 210Trp, 215Tyr 40 (11%) 40 (17%) 0 0
184Val 38 (10%) 1 27 10
41Leu, 67Asn, 184Val, 210Trp, 215Tyr 26 (7%) 26 0 0
67Asn, 70Arg, 184Val, 219Gln 18 (5%) 1 17 0
184Val, 215Tyr 15 (4%) 0 15 0
First-line NRTIs used
Zidovudine 275 (70%) 177 (80%) 86 (67%) 12 (36%)
Tenofovir 39 (10%) 19 (8%) 16 (13%) 4 (12%)
Initial second-line NRTIs prescribed
Tenofovir, lamivudine/emtricitabine 279 (71%) 159 (69%) 105 (82%) 15 (45%)
Tenofovir, zidovudine, 
lamivudine/emtricitabine*
36 (9%) 17 (7%) 8 (6%) 11 (33%)
Abacavir, didanosine 51 (13%) 40 (17%) 5 (4%) 6 (18%)
Abacavir, lamivudine/emtricitabine 12 (3%) 9 (4%) 2 (2%) 1 (3%)
Zidovudine, lamivudine/emtricitabine 10 (3%) 2 (1%) 8 (6%) 0
Didanosine, lamivudine/emtricitabine 2 (1%) 2 (1%) 0 0
Zidovudine, didanosine 1 (<1%) 1 (<1%) 0 0
Data are median (IQR) or median (IQR; range), and number of patients and % of those with baseline genotypes available in each group. Predicted-active NRTIs are prescribed 
NRTIs with no more than low-level resistance on baseline genotype. ART=antiretroviral therapy. NRTI=nucleoside reverse-transcriptase inhibitor. GSS=genotypic susceptibility 
score. TAM=thymidine analogue mutation. *An NRTI regimen of three NRTIs (tenofovir, zidovudine, and lamivudine) was initially prescribed in Malawi, but this was reduced to 
two NRTIs (usually tenofovir and lamivudine) after a median of 45 weeks from randomisation when national guidelines changed.
Table 1: Resistance at first-line failure and predicted activity of NRTIs prescribed in second-line protease inhibitor and NRTI regimen
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their prescribed second-line regimen: regimen included 
tenofovir plus lamivudine or emtricitabine in 176 (77%); 
patients had median five NRTI mutations; 75% with 
TAM1 and 69% with TAM2. 128 (33%) of 391 had 
one predicted-active NRTI prescribed: regimen included 
tenofovir plus lamivudine or emtricitabine in 113 (88%); 
median two mutations; 30% with TAM1 and 47% with 
TAM2. 33 (8%) of 391 had at least two predicted-active 
NRTIs prescribed: regimen included tenofovir plus 
lamivudine or emtricitabine in 26 (79%); median zero 
mutations.
At week 144, 176 (89%) of 198 prescribed a second-line 
protease inhibitor and NRTI regimen containing no 
predicted-active NRTIs had viral suppression (viral load 
<400 copies per mL) compared with 312 (81%) of 383 in 
the protease inhibitor and raltegravir group (risk 
difference 7·4%; 95% CI 1·6 to 13·3; p=0·02). At week 
96, 181 (88%) of 205 prescribed a regimen with no 
predicted-active NRTIs had viral suppression compared 
with 233 (61%) of 380 in the protease inhibitor 
monotherapy group (27·0%; 20·4 to 33·6; p<0·0001; 
figure). At week 144, 95 (85%) of 112 prescribed a regimen 
with one predicted-active NRTI had viral load suppression 
compared with 176 (89%) of 198 prescribed a regimen 
with no predicted-active NRTIs (–4·1%; –12·0 to 3·9; 
p=0·30). Furthermore, 20 (77%) of 26 with two to three 
predicted-active NRTIs had viral suppression (–12·0%; 
–28·7 to 4·8%; p=0·08 compared with no predicted-
active NRTIs). Across the whole follow-up period, greater 
predicted activity of prescribed NRTIs was associated 
with worse viral load suppression (global generalised 
estimating equation p=0·0004; figure). A similar pattern 
of responses for all study weeks was seen with predicted 
activity of prescribed NRTIs calculated by genotypic 
susceptibility score (p=0·003; figure), and in analyses 
including only those failing on tenofovir first-line 
(p<0·0001), with viral load thresholds of less than 
50 copies per mL (same rank, but difference attenuated, 
p=0·4; appendix p 3), or less than 1000 copies per mL 
(p=0·003; appendix p 4), and excluding patients in 
Malawi taking three NRTIs (p=0·03; appendix p 5).
In the protease inhibitor and NRTI group, increased 
viral load or reduced CD4 cell count at baseline, being 
unemployed or a student, working more hours if 
employed, and reporting being non-adherent at more 
visits were all independently associated with reduced 
probability of a viral load of less than 400 copies per mL 
at week 144 (table 2). Adjusting for these factors, 
increased genotypic susceptibility score remained 
associated with reduced probability of a viral load of less 
than 400 copies per mL (p=0·001); the effect remained 
(p=0·004) after restricting analysis to those with a 
genotypic susceptibility score of less than 2 (appendix 
p 8). Adjusting for these factors and genotypic 
susceptibility score, there was no evidence of an 
association between any individual mutation, TAM1, or 
TAM2 and a viral load of less than 400 copies per mL 
(p>0·05, data not shown). Results were very similar 
including all factors with p<0·2 on univariable analysis 
without backwards elimination, and using backward 
elimination with exit p>0·2 (appendix p 8).
Discussion
We found that NRTIs predicted by resistance testing to 
contribute limited or no antiviral activity to a protease 
inhibitor-containing second-line regimen still had sub-
stantial virological effect, at least as good as that obtained 
from a fully active drug from a new class (raltegravir). 
This suggests that in the context of a switch from a first-
line NNRTI-based to a second-line protease-inhibitor-
based regimen, predictions based on genotypic resistance 
testing might overestimate the detrimental effect of 
cross-resistance on the activity of NRTIs. Prediction of 
clinical outcomes from genotypic resistance tests is 
challenging,10,11 and algorithms might be particularly poor 
at predicting the combined effects of NRTI mutations 
that could sometimes be antagonistic.
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Figure: Viral load suppression by second-line regimen
Suppression defined as <400 copies per mL. Predicted active NRTIs are prescribed NRTIs with no more than 
low-level resistance on baseline genotype (A) By number of predicted-active NRTIs; global p<0·0001; within 
PI and NRTI group, global p<0·0004. (B) By genotypic susceptibility score; global p<0·0001; within PI and 
NRTI group, global p=0·003. GSS=genotypic susceptibility score. NRTI=nucleoside reverse-transcriptase 
inhibitor. n=minimum number of viral load values available at any follow-up timepoint in each group. 
PI=protease inhibitor. 
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In addition to our finding of substantial efficacy of 
NRTIs that had limited or no predicted activity, the 
paradoxical association we found between greater 
predicted NRTI activity and worse viral load suppression 
also contrasts with standard assumptions underlying 
resistance. Our findings are consistent with other 
second-line studies that have also found an absent or 
paradoxical association between NRTI resistance and 
outcomes,12–17 but several features of our study (especially 
the prospectively collected adherence data and availability 
of two comparison groups) allow for more robust 
interpretation. The inferior viral suppression observed in 
those individuals with two or more fully active NRTIs 
in the prescribed regimen is probably explained by 
treatment adherence: this very small group of patients 
had no resistance mutations detected at baseline and 
probably comprised those who concealed complete non-
adherence at study entry and continued to have poor 
adherence during second-line. The high viral load 
suppression in those taking NRTIs with limited or no 
predicted activity is probably not explained by residual 
confounding by adherence, elevated viral load, or other 
baseline factors associated with resistance because the 
effects persisted after adjustment. Furthermore, the 
randomised comparison of the entire protease inhibitor 
and NRTI group versus the protease inhibitor mono-
therapy group (ie, with all confounding removed) showed 
viral load suppression was increased in the protease 
inhibitor and NRTI group overall, which can only be 
because of the presence of ongoing NRTI activity.7 Our 
interpretation is further supported by a randomised 
comparison of protease inhibitor monotherapy versus 
protease inhibitor plus lamivudine as maintenance in 
second-line therapy that showed clear additional 
contribution of lamivudine despite almost universal 
lamivudine resistance.18
The observed NRTI effect might, in part, arise from 
resistance mutations such as Met184Val and Lys65Arg 
affecting viral replicative capacity, with effects increasing 
with more mutations.19–21 The effect of resistance 
mutations on viral replication fidelity might also protect 
the protease inhibitor by limiting the development of 
new mutations to escape drug pressure, thus increasing 
regimen durability.22,23 Pharmacokinetic considerations 
might enhance these benefits; NRTIs, such as tenofovir 
and lamivudine, have long intracellular half-lives that 
might help to maintain viral suppression when protease 
inhibitor levels are low (with late or occasional missed 
doses) and this effect might be independent of predicted 
activity. This potential effect could explain why we 
observed that the NRTIs were capable of matching the 
suppression obtained with raltegravir (a drug with a 
relatively short intracellular half-life) in combination 
with a protease inhibitor.
The strengths of our study include large numbers of 
patients, long follow-up, high retention, regular viral 
load testing at predetermined timepoints, centralised 
viral load and resistance testing, and the availability of 
two relevant treatment comparison groups (especially 
the protease inhibitor monotherapy group) that enable 
the contribution of NRTIs to the regimen to be delineated. 
Although patients were participating in a clinical trial, 
the trial eligibility criteria were kept broad and we 
followed the widely used approach of clinical and 
CD4 cell count monitoring (targeted viral load testing 
was done to confirm treatment failure before changing 
therapy, but there was no real-time viral load testing 
during the trial). The results are therefore probably 
generalisable to patients failing first-line therapy in 
programmes that follow the public health approach to 
ART delivery.
The main limitation of our study is that most patients 
were taking zidovudine-based first-line regimens; 
whereas, contemporary WHO guidelines recommend 
tenofovir-based first-line ART. The similar results seen in 
the analysis of the subgroup failing on first-line tenofovir, 
however, support the generalisability of our findings. The 
protease inhibitor was standardised in this trial to 
Unadjusted odds ratio 
(95% CI)
p value Adjusted odds ratio 
(95% CI)
p value
Genomic susceptibility score of second-line regimen 
(per 0·5 higher)
0·78 (0·61–0·99) 0·04 0·61 (0·46–0·81) 0·001
Proportion of non-adherent visits (per 10% higher)* 0·66 (0·55–0·79) <0·0001 0·61 (0·49–0·77) <0·0001
Unemployed or student vs employed 0·39 (0·21–0·72) 0·003 0·22 (0·07–0·63) 0·005
Hours worked by employed and students (per 10 h higher) 1·03 (0·92–1·17) 0·6 0·83 (0·70–0·99) 0·04
Baseline viral load per doubling 0·82 (0·70–0·95) 0·01 0·80 (0·67–0·97) 0·02
Baseline CD4 cell count per doubling 1·24 (1·02–1·50) 0·03 1·33 (1·04–1·71) 0·02
n=317, excluding those with missing week 144 viral load, baseline genotype or baseline employment status. Baseline refers to switch to second-line therapy (enrolment into 
the trial). Univariable analyses are in the appendix. Adjusted odds ratio adjusted for the factors given in the table. Factors not selected (p>0·05): sex, age, viral subtype, years 
on first-line antiretroviral treatment, diabetes, family history of cardiovascular disease, previous CNS disease, previous tuberculosis, smoking, alcohol consumption, 
household income, food availability, years of education, estimated glomerular filtration rate, haemoglobin, glucose, presence of individual mutations in the baseline 
genotype (where >10% prevalence), presence of combinations of 2 mutations in the baseline genotype (where >10% prevalence). *Scheduled visit that was either missed or 
where the participant self-reported missing pills since the last visit. 
Table 2: Multivariable model for viral load <400 copies per mL at week 144 in protease inhibitor and nucleoside reverse-transcriptase inhibitor group
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ritonavir-boosted lopinavir, which is recommended as a 
preferred protease inhibitor in WHO guidelines3 and 
remains widely used in treatment programmes following 
the WHO public health approach. Whether NRTIs with 
limited or no predicted activity would contribute in a 
similar way to a regimen with atazanavir (WHO preferred 
protease inhibitor) or darunavir (alternative protease 
inhibitor) is unclear, although this seems probable at 
least for darunavir on the basis of its activity with NRTI 
resistance in other second-line studies.18,24 We analysed 
our data with the Stanford algorithm, the most widely 
used. Although alternative algorithms might give slightly 
different weight to individual resistance mutations, they 
are based on the same mutations and would probably 
provide similar outcome predictions.10 Patients had non-
subtype-B virus, whereas the reference algorithms in the 
Stanford database are for subtype-B virus. Mutations 
conferring NRTI drug resistance differ little between 
subtypes, however, and do not seem to affect outcomes.25,26 
A cohort study17 in a subtype-B population drew similar 
conclusions with respect to predicted NRTI activity and 
outcomes. For our binary classification of NRTI drugs as 
active or inactive we used a cutoff (NRTI considered 
active if no more than low-level resistance) that 
corresponds to the way many clinicians interpret 
resistance tests. Although some researchers might prefer 
alternative cutoffs, we found the same results with an 
analysis based on genotypic susceptibility score that gives 
more discrimination at intermediate values of resistance, 
and on a linear regression analysis of the genotypic 
susceptibility score that dispensed entirely with cutoffs. 
Furthermore, arguments on cutoffs are irrelevant for the 
group in which there was high-level resistance to both 
NRTI drugs selected (in which genotypic susceptibility 
score=0). In this situation, most would expect little 
benefit from the prescribed drugs and yet there was clear 
evidence of a major contribution to regimen activity.
Our findings are relevant to discussions about the 
merit of introducing routine resistance testing into the 
public health approach to ART for patients switching 
to the standard protease inhibitor-based second-line 
regimen. Although genotypic resistance testing is 
recommended in treatment guidelines for individualised 
therapy and widely used by clinicians in high-income 
countries for ART drug selection at treatment failure,4–6 
the randomised controlled trials on which this practice is 
based generally showed modest short-term benefit and, 
of particular relevance to the present discussion, enrolled 
mainly patients who had failed on protease inhibitor-
based regimens.27 None of these trials specifically 
examined the benefit of genotypic resistance testing in 
patients not previously treated with a protease inhibitor 
switching from a failing NNRTI-based first-line regimen 
to a protease inhibitor-based second-line regimen. The 
lack of association between predicted NRTI activity and 
outcomes shown in our study and other observational 
studies of protease inhibitor-based second-line therapy 
supports WHO treatment guidelines that do not 
recommend resistance testing at switch to second-line 
ART in the public health approach.3 The findings also 
suggest that NRTI selection might best be based on 
minimising toxicity and maximising tolerability in 
view of the effect of these on adherence. Introducing 
resistance testing in programme settings could theo-
retically provide additional benefit by identifying patients 
without resistance mutations who might be managed 
with more adherence counselling rather than switching 
to second-line. Our data suggest the effect of this would 
also be limited, however, because such patients were 
uncommon in our population (less than 2% lacked either 
an NRTI or NNRTI mutation).22 The proportion without 
resistance mutations detected at failure might be higher 
in programmes that succeed in implementing the 
WHO recommendation of annual viral load testing, but 
in some of these cases the resistance mutations might be 
present but archived (ie, would re-emerge upon 
resumption of regular therapy). Furthermore, such 
patients might not be responsive to additional adherence 
counselling: in our trial we provided universal adherence 
counselling at first-line failure and during second-line, 
but such patients still had inferior outcomes on second-
line therapy. The NRTI drug class will probably remain 
in widespread use for millions of people in treatment 
programmes that use the public health approach (and 
elsewhere). Our results should stimulate further work to 
validate resistance-testing algorithms against NRTI 
clinical response in second-line protease inhibitor-based 
therapy and in other drug regimens. More generally, our 
findings emphasise the need for critical thinking around 
the benefits to be gained, if any, before new elements of 
care are introduced into the public health approach, even 
if they are considered as standard practice in high-income 
settings.
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